Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03604835 · ClinicalTrials.gov registry record

Mucopolysaccharidosis VII Disease Monitoring Program

A clinical trial of Mucopolysaccharidosis VII and MPS VII, sponsored by Ultragenyx Pharmaceutical.

Recruiting
Registry status
50
Enrollment target
14
Study locations

NCT03604835: Recruiting study of Mucopolysaccharidosis VII and MPS VII, sponsored by Ultragenyx Pharmaceutical.

NCT03604835 is a study of Mucopolysaccharidosis VII and MPS VII that is actively recruiting participants, run by Ultragenyx Pharmaceutical. The registered enrollment target is 50 participants. The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03604835, a study of Mucopolysaccharidosis VII and MPS VII, is actively recruiting participants, sponsored by Ultragenyx Pharmaceutical.

RECRUITING
Registry status
50 participants
Enrollment target
14
Study locations

Study Summary

The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.

Primary Outcome

To characterize MPS VII disease presentation and progression over time in patients treated and not treated with vestronidase alfa

Interventions

  • OTHER No Intervention

Study Locations (14)

Other

  • Laboratorio de Neuroquimica Dr. N.A. Chamoles S.R.L. - Buenos Aires
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Mainz
  • Centro Hospitalar do Porto - Porto
  • Hospital Universitario Virgen del Rocío Pabellón Infantil - Seville

California

  • Children's Hospital of Orange County - Orange

District of Columbia

  • Children's National Health System - Washington D.C.

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Michigan

  • University of Michigan - Ann Arbor

New York

  • New York University Langone Medical Center - New York

Utah

  • University of Utah Medical Center - Salt Lake City

Washington

  • Seattle Children's Hospital - Seattle

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2018-01-29
Est. Completion 2033-05
Ultragenyx Pharmaceutical

52 total trials

What NCT03604835 shows while recruiting

NCT03604835 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.

The record links to 4 conditions, with Mucopolysaccharidosis VII appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.

NCT03604835 lists 14 locations in 11 states (Other, California, District of Columbia).

Frequently Asked Questions

What is clinical trial NCT03604835 about?

NCT03604835 is a clinical study titled "Mucopolysaccharidosis VII Disease Monitoring Program". The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.

What is the current status of trial NCT03604835?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2018-01-29. Estimated completion is 2033-05.

What conditions does trial NCT03604835 study?

This clinical trial studies the following conditions: Mucopolysaccharidosis VII, MPS VII, Sly Syndrome, MPS 7.

What interventions are being tested in trial NCT03604835?

The interventions under investigation include: No Intervention (OTHER).

Who is sponsoring clinical trial NCT03604835?

This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03604835 being conducted?

This trial has 14 study locations across California, District of Columbia, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mucopolysaccharidosis VII

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03604835, the US trial registry maintained by the National Library of Medicine. NCT03604835 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.